RareCyte in the News

Apr 20, 2026

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment

Aug 21, 2025

RareCyte® Announces Research Grant to Investigate Molecular Profile of Circulating Trophoblasts in Fetal Growth Restriction

Jun 27, 2024

RareCyte® secures $20M financing to expand the Orion™ Spatial Biology platform including Multiplex Assay Reagents, Software and Precision Biology Services

Apr 09, 2024

Navigate BioPharma Services, Inc. announces collaboration with RareCyte, Inc. to provide enhanced spatial biology capabilities using the Orion™ Platform.

Jan 22, 2024

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

Jan 18, 2024

OPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio

Sep 26, 2023

Recent Nature publications highlight the groundbreaking performance of RareCyte's Orion Spatial Biology platform

Sep 6, 2023

Results of Recent Colorectal Immunotherapy Study Highlight the Groundbreaking Performance of RareCyte's Orion Spatial Biology Platform

Jun 29, 2023

Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan's "MITSUI LINK-Lab KASHIWA-NO-HA 1"

Nov 14, 2022

RareCyte® selected for the Wellcome Leap In Utero program; will utilize its rare cell liquid biopsy platform to perform breakthrough research to decrease stillbirth rates worldwide

Nov 3, 2022

The GastroIntestinal Research Foundation Launches New Multi-Million Dollar Funding Initiative Aimed at Curing Cancers of the Digestive System

Jun 01, 2021

RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignancies